69P Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups
Titel:
69P Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups
Auteur:
Choy, J. Rodriguez, C. Suarez Larkin, J. Patel, P. Valderrama, B. Perez Rodriguez-Vida, A. Glen, H. Thistlethwaite, F. Ralph, C. Srinivasan, G. Vidal, M.J. Mendez Carter, A. Tyson, C. Prendergast, A. Mousa, K. Powles, T.B. Szabados, B.E.